Gewinn- und Verlustrechnung von Royalty Pharma plc

Eastern Bank raised its position in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 2.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 708,768 shares of the biopharmaceutical company's stock after buying an additional 13,843 shares during the quarter. Eastern Bank

Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.

Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value of $5,853,000.00. Following the completion of the transaction, the executive vice president directly owned 270,401 shares of

Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.

Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.